Shots: The US FDA has granted FT designation to ADX-2191 for the prevention of proliferative vitreoretinopathy and provides it eligibility for Priority Review and rolling NDA submission The FDA’s FT […]readmore
Tags : Proliferative Vitreoretinopathy